Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib maintenance after first-line platinum response in advanced ovarian cancer
2023-508010-42-00Phase 3Completed
- Sponsor
- TESARO, Inc.
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Niraparib maintenance with Placebo maintenance (2 arms). Primary endpoint: Progression-free survival. Started May 2024; status: completed.
02
Drugs
niraparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2023-508010-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508010-42-00.